Improvement in asthma control and reduction in medical resource use following treatment with montelukast (PRAACTICAL Study) Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005
Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality: INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations) study Source: Eur Respir J 2007; 30: Suppl. 51, 34s Year: 2007
Incidence of asthma-related hospitalizations with the addition of salmeterol to an ICS in subjects with asthma: a meta-analysis Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007
Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study Source: Eur Respir J, 54 (6) 1900901; 10.1183/13993003.00901-2019 Year: 2019
Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007
Patterns of risk of death and asthma-related adverse outcomes in adult asthma patients receiving long-acting β2 -agonist (LABA) therapy: results from the UK general practice research database (GPRD) Source: Annual Congress 2009 - Asthma treatment and control strategies in primary care Year: 2009
Effect of treatment with tiotropium bromide 18 mcg on asthma control and asthma-related quality of life in patients with asthma-COPD overlap syndrome. Source: International Congress 2017 – Techniques to treat asthma Year: 2017
Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004
Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Asthma total costs reduction and clinical improvement after inhaled steroid shift to fluticasone propionate during 1 year in patients with moderate to severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 56s Year: 2002
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2 -agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011
Costs of asthma are correlated with severity: a 1-yr prospective study Source: Eur Respir J 2002; 19: 61-67 Year: 2002
Changes in prescriped inhaled COPD medication during a 3 year period in Denmark. A registry study Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013
Healthcare resource use following addition of montelukast to budesonide compared to doubling the dose of budesonide in patients with inadequately controlled asthma (COMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004